

Please join us for an
educational program

XOFLUZA:

THE ONLY SINGLE-DOSE ORAL TREATMENT AND POST-EXPOSURE PROPHYLAXIS FOR FLU

09/07/2021

Arrival Time: 6:15 PM CST

Presentation Time: 6:30 PM CST

EVENT LOCATION:

Sinclair's East

7847 Vaughn Rd

Montgomery, AL 36116


PRESENTED BY

Marilyn Bulloch

Associate Clinical Professor and Director of Strategic Operations
Harrison School of Pharmacy at Auburn University & DCH Regional
Medical Center

RSVP AND PROGRAM DETAILS TO REGISTER FOR THIS EVENT, PLEASE VISIT

[GENENTECHRSVP.COM](https://www.genentech.com/RSVP) AND REFERENCE EVENT
NUMBER CM41175.



PROGRAM HIGHLIGHTS



Consider

the evidence for XOFLUZA[®] in flu
treatment and post-exposure prophylaxis



Learn

how to counsel your flu patients on XOFLUZA[®]

Indication

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

- Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:
 - Otherwise healthy, or
 - At high risk of developing influenza-related complications
- Post-exposure prophylaxis (PEP) of influenza in patients 12 years of age and older following contact with an individual who has influenza

Limitations of Use

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Please see Important Safety Information on page 2.



IMPORTANT SAFETY INFORMATION

Contraindications

XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

Warnings and Precautions

- **Hypersensitivity:** Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.
- **Risk of bacterial infections:** There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

- The most common adverse reactions (≥1%) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
- The most common adverse reaction in a clinical study for post-exposure prophylaxis (PEP) was nasopharyngitis (6%).

Drug Interactions

- **Polyvalent cations:** Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).
- **Vaccines:** The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

For additional important safety information, please see the XOFLUZA full [Prescribing Information](#).

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

This event is sponsored by Genentech USA, Inc. No continuing education credits are offered with this program.

Minnesota, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program.

For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).

The meal value reported may vary by event location and be up to \$150 per person (exceptions may apply).